Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04080804 |
|
Recruitment Status :
Recruiting
First Posted : September 6, 2019
Last Update Posted : April 4, 2022
|
Sponsor:
Robert Ferris
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Robert Ferris, University of Pittsburgh
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 2023 |
| Estimated Study Completion Date : | October 2026 |